Key facts
- This page summarizes Anson Funds Management LP's Form 4 filing for MEI Pharma, Inc. (MEIP).
- 5 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 24 Oct 2023, 19:32.
Anson Funds Management LP - 20 Oct 2023 Form 4 Insider Report for MEI Pharma, Inc. (MEIP)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MEIP
- Reported as of
- 20 Oct 2023
- Net transaction value
- +$1,253,000
- SEC form
- 4
- Accepted by SEC
- 24 Oct 2023, 19:32:56 UTC
- Prior SEC filing
- 13 Oct 2023
- Next SEC filing
- 26 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bruce R. Winson, manager of Anson Management GP LLC, general partner of Anson Funds Management LP
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Anson Funds Management LP filed Form 4 for MEI Pharma, Inc. (MEIP) on 24 Oct 2023.
Change
- Previous filing in this sequence was filed on 13 Oct 2023.
- Current net transaction value: +$1,253,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MEIP
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $1,002,400
- Shares
- +143,200
- Change %
- +16%
- Price
- $7.00
- Shares after
- 1,057,388
- Date
- 20 Oct 2023
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
MEIP
transaction
Common Stock
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $250,600
- Shares
- +35,800
- Change %
- +3.4%
- Price
- $7.00
- Shares after
- 1,093,188
- Date
- 20 Oct 2023
- Ownership
- See footnotes
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MEIP
transaction
Derivative
Put Option (obligation to buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -1,432
- Change %
- -17%
- Price
- $0.000000
- Shares after
- 7,068
- Date
- 20 Oct 2023
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 143,200
- Exercise price
- $7.00
- Footnotes
- F1, F2, F3
MEIP
transaction
Derivative
Put Option (obligation to buy)
Exercise of in-the-money or at-the-money derivative security
- Transaction value
- $0
- Shares
- -358
- Change %
- -5.1%
- Price
- $0.000000
- Shares after
- 6,710
- Date
- 20 Oct 2023
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 35,800
- Exercise price
- $7.00
- Footnotes
- F1, F2, F3
MEIP
transaction
Derivative
Put Option (obligation to buy)
Expiration of short derivative position
- Transaction value
- $0
- Shares
- -6,710
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 20 Oct 2023
- Ownership
- See footnotes
- Underlying class
- Common Stock
- Underlying amount
- 671,000
- Exercise price
- $7.00
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.
Footnote F2
Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
Footnote F3
Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.